LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.

Novo Nordisk A/S’ (NYSE:NVO) executives allegedly ignored internal warnings that the company was unprepared to launch its ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...

Memorial Hermann is laying off 83 employees due to the closure of the University Place senior living community and nursing ...